EW · XBRL financial data

Edwards Lifesciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EW's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	4,386	5,233	5,382	6,005	5,440	6,068
Cost of goods and services sold	1,081	1,249	1,080	1,380	1,118	1,334
Gross profit	3,306	3,984	4,302	4,625	4,322	4,733
Research and development	761	903	945	1,072	1,053	1,079
Selling, general and administrative	1,228	1,494	1,568	1,825	1,789	2,085
Other operating income (expense)	—	—	0	0	0	67
Operating income (loss)	898	1,690	1,749	1,534	1,379	1,264
Interest income	23	17	36	67	120	169
Interest expense	16	18	19	18	20	20
Other income (expense)	12	13	3	14	69	7
Income tax expense (benefit)	93	199	246	199	152	217
Net income (loss)	—	1,503	1,522	1,402	4,175	1,074
Earnings per share, basic USD per share	1.32	2.41	2.46	2.31	6.98	1.84
Earnings per share, diluted USD per share	1.30	2.38	2.44	2.30	6.97	1.83
Weighted average shares, basic millions of shares	623	623	619	607	598	585
Weighted average shares, diluted millions of shares	632	631	624	609	599	586

Fiscal years (EW's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,183	863	769	1,144	3,045	2,938
Short-term investments	219	604	446	501	931	1,288
Accounts receivable	515	582	643	775	609	660
Inventory	802	727	876	1,168	1,087	1,126
Total current assets	3,091	3,181	3,096	4,036	6,285	6,739
Property and equipment, net	1,395	1,547	1,633	1,749	1,686	1,812
Right-of-use asset	94	92	92	94	98	103
Goodwill	1,173	1,168	1,164	1,254	1,777	1,769
Total assets	7,237	8,503	8,293	9,363	13,055	13,697
Accounts payable	197	205	202	201	197	228
Total current liabilities	894	1,032	1,022	1,195	1,505	1,814
Long-term debt	595	596	596	597	598	598
Lease liability, non-current	73	69	70	73	79	83
Total liabilities	2,663	2,667	2,486	2,644	2,992	3,360
Retained earnings	4,565	6,068	7,590	8,992	13,167	14,241
Total stockholders' equity	4,574	5,836	5,807	6,650	9,998	10,338
Total liabilities and equity	7,237	8,503	8,293	9,363	13,055	13,697
Common shares outstanding (cover page) millions of shares	625	623	608	601	588	581

Fiscal years (EW's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	1,503	1,522	1,402	4,175	1,074
Stock-based compensation	93	109	127	139	162	158
Depreciation and amortization	107	135	140	145	155	157
Net cash from operating activities	1,054	1,732	1,218	896	542	1,595
Purchases of property and equipment	407	326	245	253	252	260
Net cash from investing activities	(531)	(1,723)	252	174	2,313	(713)
Share repurchases	625	513	1,727	880	1,159	893
Proceeds from long-term debt	16	5	0	0	—	—
Net cash from financing activities	(487)	(356)	(1,585)	(711)	(983)	(957)
Net change in cash	16	(333)	(95)	375	1,911	(119)

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Edwards Lifesciences	2,907	1,741	652*	576.4M	—	Q2 FY26 10-QJun 30, 2026
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	—	Q3 FY26 10-QJun 30, 2026
3M	4,835	6,584	486*	516.7M	—	Q3 FY26 10-QSep 30, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Insulet	not reported	842	not reported	69.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.